Equities research analysts predict that Magenta Therapeutics Inc (NASDAQ:MGTA) will announce ($0.55) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Magenta Therapeutics’ earnings, with estimates ranging from ($0.55) to ($0.54). The business is scheduled to issue its next quarterly earnings report on Thursday, February 14th.
On average, analysts expect that Magenta Therapeutics will report full year earnings of ($3.19) per share for the current financial year, with EPS estimates ranging from ($3.23) to ($3.15). For the next financial year, analysts expect that the business will post earnings of ($2.05) per share, with EPS estimates ranging from ($2.67) to ($1.12). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Magenta Therapeutics.
Magenta Therapeutics (NASDAQ:MGTA) last released its earnings results on Thursday, November 8th. The company reported ($0.49) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.67) by $0.18.
A number of research firms have issued reports on MGTA. Zacks Investment Research raised shares of Magenta Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 10th. ValuEngine lowered shares of Magenta Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, January 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $19.33.
Several large investors have recently modified their holdings of MGTA. Point72 Hong Kong Ltd acquired a new stake in Magenta Therapeutics during the second quarter valued at approximately $109,000. Point72 Asset Management L.P. acquired a new stake in shares of Magenta Therapeutics during the second quarter valued at approximately $109,000. Northern Trust Corp acquired a new stake in shares of Magenta Therapeutics during the second quarter valued at approximately $179,000. Bollard Group LLC acquired a new stake in shares of Magenta Therapeutics during the third quarter valued at approximately $360,000. Finally, Platinum Investment Management Ltd. acquired a new stake in shares of Magenta Therapeutics during the second quarter valued at approximately $675,000. 30.79% of the stock is owned by institutional investors.
MGTA opened at $6.12 on Friday. Magenta Therapeutics has a 1-year low of $5.31 and a 1-year high of $16.33.
About Magenta Therapeutics
Magenta Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases.
Further Reading: What are the Different Types of Leveraged Buyouts?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.